Posaconazole
규격
171228-49-2CAS 번호
682-747-8EC 번호
4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-oneIUPAC 명칭
C37H42F2N8O4화학식
700.8 g/mol분자량
Posaconazole; 171228-49-2; Noxafil; Sch 56592; SCH-56592; SCH56592; posaconazol; Schering 56592; 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one; DTXSID6049066; (-)-POSACONAZOLE; 6TK1G07BHZ; CHEBI:64355; DTXCID401474254; 2,5-anhydro-1,3,4-trideoxy-2-(2,4-difluorophenyl)-4-({4-[4-(4-{1-[(2S,3S)-2-hydroxypentan-3-yl]-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl}phenyl)piperazin-1-yl]phenoxy}methyl)-1-(1H-1,2,4-triazol-1-yl)-D-threo-pentitol; 4-(p-(4-(p-(((3R,5R)-5-(2,4-Difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furyl)methoxy)phenyl)-1-piperazinyl)phenyl)-1-((1S,2S)-1-ethyl-2-hydroxypropyl)-delta(sup 2)-1,2,4-triazolin-5-one; posaconazolum; 2,5-anhydro-1,3,4-trideoxy-2-(2,4-difluorophenyl)-4-((4-(4-(4-(1-((2S,3S)-2-hydroxypentan-3-yl)-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl)phenyl)piperazin-1-yl)phenoxy)methyl)-1-(1H-1,2,4-triazol-1-yl)-D-threo-pentitol; 4-(4-(4-(4-(((3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-((2S,3S)-2-hydroxypentan-3-yl)-1,2,4-triazol-3-one; RefChem:56731; Posaconazole Delayed-Release; NOXAFIL POWDERMIX KIT; J02AC04; 4-(4-(4-(4-(((5R)-5-(2,4-difluorophenyl)-5-(1H-1,2,4-triazol-1-ylmethyl)oxolan-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-1-((2S,3S)-2-hydroxypentan-3-yl)-4,5-dihydro-1H-1,2,4-triazol-5-one; Posaconazole SP; 4-(4-(4-(4-(((3R,5R)-5-((1H-1,2,4-TRIAZOL-1-YL)METHYL)-5-(2,4-DIFLUOROPHENYL)TETRAHYDROFURAN-3-YL)METHOXY)PHENYL)PIPERAZIN-1-YL)PHENYL)-1-((2S,3S)-2-HYDROXYPENTAN-3-YL)-1H-1,2,4-TRIAZOL-5(4H)-ONE; MFCD00941162; C37H42F2N8O4; CHEMBL1397; MMV688774; 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)tetrahydrofuran-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(1S,2S)-1-ethyl-2-hydroxy-propyl]-1,2,4-triazol-3-one; POS; CAS-171228-49-2; UNII-6TK1G07BHZ; pasaconazole; Posanol; Spriafil; Posaconazole?; Posaconazole [USAN:INN:BAN]; HSDB 7421; NCGC00185736-01; 3H-1,2,4-Triazol-3-one, 4-(4-(4-(4-((5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furanyl)methoxy)phenyl)-1-piperazinyl)phenyl)-2-(1-ethyl-2-hydroxypropyl)-2,4-dihydro-, (3R-(3alpha(1S*,2S*),5alpha))-; 3H-1,2,4-Triazol-3-one, 4-[4-[4-[4-[[5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furanyl]methoxy]phenyl]-1-piperazinyl]phenyl]-2-(1-ethyl-2-hydroxypropyl)-2,4-dihydro-, [3R-[3alpha(1S*,2S*),5alpha]]-; D-threo-Pentitol, 2,5-anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-[[4-[4-[4-[1-[(1S,2S)-1-ethyl-2-hydroxypropyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]phenyl]-1-piperazinyl]phenoxy]methyl]-1-(1H-1,2,4-triazol-1-yl)-; Noxafil; Posaconazole; Sch 56592; Noxafil (TN); Posaconazole - Form I; Posaconazole (Standard); Posaconazole - Form III; POSACONAZOLE [MI]; POSACONAZOLE [INN]; POSACONAZOLE [JAN]; POSACONAZOLE [HSDB]; POSACONAZOLE [USAN]; POSACONAZOLE [VANDF]; POSACONAZOLE [MART.]; 177571-33-4; POSACONAZOLE [WHO-DD]; SCHEMBL991747; orb1300976; orb3141223; Posaconazole (JAN/USAN/INN); POSACONAZOLE [EMA EPAR]; SCHEMBL29372531; GTPL11428; Posaconazole - Bio-X trade mark; POSACONAZOLE [GREEN BOOK]; GLXC-05188; POSACONAZOLE [ORANGE BOOK]; Tox21_113620; BDBM50181473; EBC-11286; HY-17373R; MSK156847; s1257; AKOS005145917; Tox21_113620_1; AC-1350; CCG-270387; CS-0998; DB01263; FP27107; KS-1413; NCGC00274060-01; NCGC00274060-02; NCGC00274060-07; 2,5-Anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-[[4-[4-[4-[1-[(1S,2S)-1-ethyl-2-hydroxypropyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]phenyl]-1-piperazinyl]phenoxy]methyl]-1-(1H-1,2,4-triazol-1-yl)-D-threo-pentitol; 4-{4-[4-(4-{[(3R,5R)-5-(2,4-difluorophenyl)-5-[(1H-1,2,4-triazol-1-yl)methyl]oxolan-3-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-1-[(2S,3S)-2-hydroxypentan-3-yl]-4,5-dihydro-1H-1,2,4-triazol-5-one; BP163592; BP163593; BP164281; D-threo-Pentitol, 2,5-anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)- 4-((4-(4-(4-(1-((1S,2S)-1-ety; HY-17373; Posaconazole in combination with MGCD290; SY107631; NS00002082; P2477; SW219391-1; T6211; D02555; SBI-0654141.0001; AB01274762-01; AB01274762_02; Posaconazole, VETRANAL(TM), analytical standard; EN300-19769273; Q906453; BRD-K06222852-001-03-2; BRD-K06222852-001-05-7; 1-((1S,2S)-1-Ethyl-2-hydroxypropyl)-4-{4-[4-(4-{[(5S,3R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazolylmethyl)oxolan-3-yl]methoxy}phenyl)piperazinyl]phenyl}-1,2,4-triazolin-5-one; 2,5-anhydro-1,3,4-trideoxy-2-(2,4-difluorophenyl)-4-({4-[4-(4-{1-[(1S,2S)-1-ethyl-2-hydroxypropyl]-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl}phenyl)piperazin-1-yl]phenoxy}methyl)-1-(1H-1,2,4-triazol-1-yl)-D-threo-pentitol; 2,5-Anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-[[4-[4-[4-[1-[(1S ,2S)-1-ethyl-2-hydroxypropyl]-1,5-dihydro-5-oxo-4H-1,2,4-tria zol-4-yl]phenyl]-1-piperazinyl]phenoxy]methyl]-1-(1H-1,2 ,4-triazol-1-yl)-D-threo-pentitol; 4-(4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)-tetrahydrofuran-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-((2S,3S)-2-hydroxypentan-3-yl)-2H-1,2,4-triazol-3(4H)-one; 4-(4-(4-(4-(((3R,5R)-5-((1H-1,2,4-TRIAZOL-1-YL)METHYL)-5-(2,4-DIFLUOROPHENYL)TETRAHYDROFURAN-3-YL)METHOXY)PHENYL)PIPERAZIN-1-YL)PHENYL)-2-((2S,3S)-2-HYDROXYPENTAN-3-YL)-2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE; 4-(4-(4-(4-(((5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)-tetrahydrofuran-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-((2S,3S)-2-hydroxypentan-3-yl)-2H-1,2,4-triazol-3(4H)-one; 4-[4-(4-{4-[(R)-5-(2,4-difluoro-phenyl)-5-(4,5-dihydro-[1,2,4]triazol-1-ylmethyl)-tetrahydro-furan-3-ylmethoxy]-phenyl}-piperazin-1-yl)-phenyl]-2-((1S,2S)-1-ethyl-2-hydroxy-propyl)-2,4-dihydro-[1,2,4]triazol-3-one; D-threo-Pentitol, 2,5-anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-((4-(4-(4-(1-((1S,2S)-1-etyl-2-hydroxypropyl)-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl)phenyl)-1-piperazinyl)phenoxy)methyl)-1-(1H-1,2,4-triazol-1-yl)-; D-threo-Pentitol, 2,5-anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-[[4-[4-[4-[1-[(1S,2S)-1-ethyl-2-hydroxypropyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]phenyl]-1-piperazinyl]phenoxy]methyl]-1-( 1H-1,2,4-triazol-1-yl)-?; D-threo-Pentitol, 2,5-anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-[[4-[4-[4-[1-[(1S,2S)-1-ethyl-2-hydroxypropyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]phenyl]-1-piperazinyl]phenoxy]methyl]-1-(1H-1,2,4-triazol-1-yl)-; PCZ; Posaconazole Micronized동의어
Posaconazole 함유 제품
녹사필장용정100밀리그램(포사코나졸(미분화))녹사필현탁액(포사코나졸(미분화))POSACONAZOL VIVANTA 100 MG COMPRIMIDOS GASTRORRESISTENTES EFGPOSACONAZOL TILLOMED 40 MG/ML SUSPENSION ORAL EFGPOSACONAZOL TARBIS 300 MG CONCENTRADO PARA SOLUCION PARA PERFUSION EFGPOSACONAZOL TARBIS 100 MG COMPRIMIDOS GASTRORRESISTENTES EFGPOSACONAZOL FRESENIUS KABI 100 MG COMPRIMIDOS GASTRORRESISTENTESPOSACONAZOL AUROVITAS 100 MG COMPRIMIDOS GASTRORRESISTENTES EFGPOSACONAZOL ALTAN 300 MG CONCENTRADO PARA SOLUCION PARA PERFUSION EFGPOSACONAZOL ALMOVAR 100 MG COMPRIMIDOS GASTRORRESISTENTES EFGPOSACONAZOL AHCL 40 MG/ML SUSPENSION ORAL EFGPOSACONAZOL ACCORD 300 MG CONCENTRADO PARA SOLUCION PARA PERFUSION EFG
1/7 페이지
Posaconazole 판매 기업
DR
Dr. Reddy's LaboratoriesIndiaML
MSN LaboratoriesIndiaSI
Sinoway Industrial Co.Ltd.ChinaTC
Tianjin Chempharmatech.Co.,Ltd.China1/6 페이지